Cancer therapy resistance: chasing epigenetics.
Cancer therapy resistance: chasing epigenetics.
复制标题
癌症治疗抵抗：追逐表观遗传学。
作者：
T-ALL是一种罕见的侵袭性白血病，其特征是信号蛋白NOTCH1(参考文献)的激活突变。5)。用常规化疗治疗这种疾病常常伴随着治疗失败，复发或难治性T-ALL患者的预后极差。几种称为GSI的Notch抑制剂已经被开发出来。虽然这些化合物具有相当大的临床前活性，但它们在临床试验中的使用尚未转化为显著的人类临床反应，部分原因是耐药性的产生。
T-ALL is a rare type of aggressive leukemia characterized by activating mutations in the signaling protein NOTCH1 (ref. 5). Treatment of this disease with conventional chemotherapy is frequently associated with therapy failure, and the prognosis of patients with relapsed or refractory T-ALL is extremely poor. Several Notch inhibitors, known as GSIs, have been developed. Although these compounds have considerable preclinical activity, their use in clinical trials has not yet translated into significant human clinical responses, in part owing to the development of resistance6.